Tech Company Financing Transactions
SonoThera Funding Round
Vida Ventures, Alexandria Venture Investments and Arch Venture Partners participated in a $125 million Series B venture round for SonoThera. The round was announced on 6/10/2026.
Transaction Overview
Company Name
Announced On
6/10/2026
Transaction Type
Venture Equity
Amount
$125,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to advance its lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD) into the clinic and expand its pipeline of targeted, redosable genetic medicines.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
201 Haskins Way 5th Floor
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
SonoThera is expanding the possibilities of disease treatment with ultrasound-guided nonviral gene therapy for diseases with suboptimal or non-existent treatments. We aim to improve the lives and health of millions of people. Our mission is to develop genetic medicines that treat the root cause of human disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Michael Davidson
Chief Executive Officer
Kenneth Greenberg
Chief Scientific Officer
Steve Feinstein
Browse more venture capital transactions:
Prev: 6/10/2026: Trustap venture capital transaction
Next: 6/10/2026: Nanordica Medical venture capital transaction
Share this article
Where The Data Comes From
We do our best to record all VC transactions involving tech companies. VC investment data records reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs